Killer Immunoglobulin-like Receptors and Tumor Immunity

被引:46
作者
Benson, Don M., Jr.
Caligiuri, Michael A.
机构
[1] Ohio State Univ, James Canc Hosp, Ctr Comprehens Canc, Dept Internal Med,Div Hematol, Columbus, OH USA
[2] Solove Res Inst, Columbus, OH USA
关键词
NK CELL-RECEPTOR; MHC CLASS-I; INHIBITORY KIR; HLA-C; LIGAND MISMATCH; PHASE-1; TRIAL; TRANSPLANTATION; ANTIBODY; COMPLEX; IPH2101;
D O I
10.1158/2326-6066.CIR-13-0219
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Natural killer (NK) cells, large granular lymphocytes comprising a key cellular subset of innate immunity, were originally named for their capacity to elicit potent cytotoxicity against tumor cells independent of prior sensitization or gene rearrangement. This process is facilitated through the expression of activating and inhibitory receptors that provide for NK cell "education" and a subsequent ability to survey, recognize, and lyse infected or transformed cells, especially those lacking or possessing mutated MHC class I expression. Since these original observations were made, how NK cells recognize candidate target cells continues to be the topic of ongoing investigation. It is now appreciated that NK cells express a diverse repertoire of activating and inhibitory receptors of which killer immunoglobulin-like receptors (KIR) appear to play a critical role in mediating self-tolerance as well as facilitating cytotoxicity against infected or transformed cells. In addition, in the presence of an activating signal, the absence or mismatch of MHC class I molecules on such targets (which serve as inhibitory KIR ligands) promotes NK cell-mediated lysis. An increasing understanding of the complexities of KIR biology has provided recent opportunities to leverage the NK cell versus tumor effect as a novel avenue of immunotherapy for cancer. The present review summarizes the current understanding of KIR expression and function and highlights ongoing efforts to translate these discoveries into novel NK cell-mediated immunotherapies for cancer. (C) 2014 AACR.
引用
收藏
页码:99 / 104
页数:6
相关论文
共 49 条
[1]   Coevolution of Killer Cell Ig-Like Receptors with HLA-C To Become the Major Variable Regulators of Human NK Cells [J].
Aguilar, Anastazia M. Older ;
Guethlein, Lisbeth A. ;
Adams, Erin J. ;
Abi-Rached, Laurent ;
Moesta, Achim K. ;
Parham, Peter .
JOURNAL OF IMMUNOLOGY, 2010, 185 (07) :4238-4251
[2]   Human NK cell education by inhibitory receptors for MHC class I [J].
Anfossi, Nicolas ;
Andre, Pascale ;
Guia, Sophie ;
Falk, Christine S. ;
Roetynck, Sophie ;
Stewart, C. Andrew ;
Breso, Violette ;
Frassati, Coralie ;
Reviron, Denis ;
Middleton, Derek ;
Romagne, Francois ;
Ugolini, Sophie ;
Vivier, Eric .
IMMUNITY, 2006, 25 (02) :331-342
[3]   Effect of Donor KIR2DL1 Allelic Polymorphism on the Outcome of Pediatric Allogeneic Hematopoietic Stem-Cell Transplantation [J].
Bari, Rafijul ;
Rujkijyanont, Piya ;
Sullivan, Erin ;
Kang, Guolian ;
Turner, Victoria ;
Gan, Kwan ;
Leung, Wing .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (30) :3782-+
[4]   Significant functional heterogeneity among KIR2DL1 alleles and a pivotal role of arginine245 [J].
Bari, Rafijul ;
Bell, Teresa ;
Leung, Wai-Hang ;
Vong, Queenie P. ;
Chan, Wing Keung ;
Das Gupta, Neha ;
Holladay, Martha ;
Rooney, Barbara ;
Leung, Wing .
BLOOD, 2009, 114 (25) :5182-5190
[5]  
Benson DM, 2012, BLOOD, V120, p4058a
[6]   A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma [J].
Benson, Don M., Jr. ;
Hofmeister, Craig C. ;
Padmanabhan, Swaminathan ;
Suvannasankha, Attaya ;
Jagannath, Sundar ;
Abonour, Rafat ;
Bakan, Courtney ;
Andre, Pascale ;
Efebera, Yvonne ;
Tiollier, Jerome ;
Caligiuri, Michael A. ;
Farag, Sherif S. .
BLOOD, 2012, 120 (22) :4324-4333
[7]   IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect [J].
Benson, Don M., Jr. ;
Bakan, Courtney E. ;
Zhang, Shuhong ;
Collins, Shauna M. ;
Liang, Jing ;
Srivastava, Shivani ;
Hofmeister, Craig C. ;
Efebera, Yvonne ;
Andre, Pascale ;
Romagne, Francois ;
Blery, Mathieu ;
Bonnafous, Cecile ;
Zhang, Jianying ;
Clever, David ;
Caligiuri, Michael A. ;
Farag, Sherif S. .
BLOOD, 2011, 118 (24) :6387-6391
[8]   Association of Killer Cell Immunoglobulin-Like Receptor Genes with Hodgkin's Lymphoma in a Familial Study [J].
Besson, Caroline ;
Roetynck, Sophie ;
Williams, Fionnuala ;
Orsi, Laurent ;
Amiel, Corinne ;
Lependeven, Catherine ;
Antoni, Guillemette ;
Hermine, Olivier ;
Brice, Pauline ;
Ferme, Christophe ;
Carde, Patrice ;
Canioni, Danielle ;
Briere, Josette ;
Raphael, Martine ;
Nicolas, Jean-Claude ;
Clavel, Jacqueline ;
Middleton, Derek ;
Vivier, Eric ;
Abel, Laurent .
PLOS ONE, 2007, 2 (05)
[9]   Human natural killer cells [J].
Caligiuri, Michael A. .
BLOOD, 2008, 112 (03) :461-469
[10]   At the Bedside: CTLA-4-and PD-1-blocking antibodies in cancer immunotherapy [J].
Callahan, Margaret K. ;
Wolchok, Jedd D. .
JOURNAL OF LEUKOCYTE BIOLOGY, 2013, 94 (01) :41-53